Denis S.
- Country
- France
- Department
- Unité de Recherche Clinique du service d’hépatogastroentérologie et oncologie digestive
Research Overview
- Phase II Randomized Trial of Chemotherapy Regimens with or without Bevacizumab in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 306 of 599 partner sites.
Specializations
Colorectal Cancer Research
Specialized in investigating novel therapeutic approaches for colorectal cancer, with particular emphasis on targeted therapies and immunotherapy treatments.
- KRAS/BRAF mutation studies
- Microsatellite Instability (MSI) research
- Circulating tumor DNA analysis
Conducts investigations into personalized treatment strategies for various stages of colorectal cancer, from early-stage to metastatic disease.
Gastric Cancer Studies
Focuses on advancing treatment options for gastric and gastroesophageal junction adenocarcinomas, incorporating novel therapeutic combinations.
- HER2-targeted treatments
- Immunotherapy applications
- Advanced metastatic disease management
Explores innovative treatment approaches for both localized and metastatic gastric cancer.
Neuroendocrine Tumors
Investigates treatment strategies for gastrointestinal neuroendocrine tumors, focusing on both traditional and innovative therapeutic approaches.
- Digestive neuroendocrine carcinomas
- Pancreatic neuroendocrine tumors
- Novel therapeutic combinations
Evaluates neoadjuvant and systemic treatment options for various grades of neuroendocrine tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.